Morpholino

MO1-opn3

ID

ZDB-MRPHLNO-250721-1

Name

MO1-opn3

Previous Names

None

Target

opn3 (1)

Sequence

5' - AAGACATGGACTTACCATTTTAACT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Splice-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-opn3

No data available

Phenotype

Phenotype resulting from MO1-opn3

Phenotype	Fish	Figures
brain vasculature decreased distribution, abnormal	y1Tg + MO1-opn3	Fig. 8 from Luo et al., 2025
dorsal longitudinal anastomotic vessel absence of anatomical entity, abnormal	y1Tg + MO1-opn3	Fig. 7 , Fig. 8 from Luo et al., 2025
intersegmental vein absence of anatomical entity, abnormal	y1Tg + MO1-opn3	Fig. 8 from Luo et al., 2025
intersegmental vein decreased length, abnormal	y1Tg + MO1-opn3	Fig. 7 , Fig. 8 from Luo et al., 2025
intersegmental vein decreased thickness, abnormal	y1Tg + MO1-opn3	Fig. 7 from Luo et al., 2025
intersegmental vein structurally discontinuous, abnormal	is5Tg + MO1-opn3	Fig. 7 , Fig. 8 from Luo et al., 2025
whole organism Ab1-opn3 labeling decreased amount, abnormal	y1Tg + MO1-opn3	Fig. 7 , Fig. 8 from Luo et al., 2025
whole organism Ab6-kdrl labeling decreased amount, abnormal	y1Tg + MO1-opn3	Fig. 8 from Luo et al., 2025
whole organism ab5-akt labeling decreased amount, abnormal	y1Tg + MO1-opn3	Fig. 8 from Luo et al., 2025

Phenotype of all Fish created by or utilizing MO1-opn3

Phenotype	Fish	Conditions	Figures
intersegmental vein absence of anatomical entity, abnormal	is5Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
brain vasculature decreased distribution, abnormal	is5Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
intersegmental vein structurally discontinuous, abnormal	is5Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
dorsal longitudinal anastomotic vessel absence of anatomical entity, abnormal	is5Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
intersegmental vein decreased length, abnormal	y1Tg + MO1-opn3	control	Fig. 7 , Fig. 8 from Luo et al., 2025
whole organism ab5-akt labeling amount, ameliorated	y1Tg + MO1-opn3	chemical treatment by injection: SC79	Fig. 8 from Luo et al., 2025
intersegmental vein morphology, ameliorated	y1Tg + MO1-opn3	chemical treatment by injection: SC79	Fig. 8 from Luo et al., 2025
dorsal longitudinal anastomotic vessel absence of anatomical entity, abnormal	y1Tg + MO1-opn3	control	Fig. 7 , Fig. 8 from Luo et al., 2025
intersegmental vein structurally discontinuous, abnormal	y1Tg + MO1-opn3	control	Fig. 7 , Fig. 8 from Luo et al., 2025
intersegmental vein absence of anatomical entity, abnormal	y1Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
dorsal longitudinal anastomotic vessel morphology, ameliorated	y1Tg + MO1-opn3	chemical treatment by injection: SC79	Fig. 8 from Luo et al., 2025
whole organism Ab1-opn3 labeling decreased amount, abnormal	y1Tg + MO1-opn3	control	Fig. 7 , Fig. 8 from Luo et al., 2025
whole organism Ab6-kdrl labeling decreased amount, abnormal	y1Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
intersegmental vein decreased thickness, abnormal	y1Tg + MO1-opn3	control	Fig. 7 from Luo et al., 2025
whole organism ab5-akt labeling decreased amount, abnormal	y1Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
brain vasculature decreased distribution, abnormal	y1Tg + MO1-opn3	control	Fig. 8 from Luo et al., 2025
brain vasculature spatial pattern, ameliorated	y1Tg + MO1-opn3	chemical treatment by injection: SC79	Fig. 8 from Luo et al., 2025

Citations